Quantifying DNA damage is mandatory to assess potential adverse effects of candidate, drugs, molecules or extracts developed in dermo-cosmetic industry. Different assays can be performed to detect primary DNA damages, such as γH2AX or the single cell gel electrophoresis also known as the comet assay. The High Content Imaging technology was used as a valuable tool for screening in early discovery phase.

Four non genotoxic compounds and twelve genotoxic compounds from the ECVAM list I or II were selected to be tested on different cell models.  Preliminary results on Mitomycine C, 4 Nitroquinoline-N-oxide and D-mannitol are shown here.

View and download on Slideshare (low quality) :

Ask for high quality link  by putting your email below


Grégory MAUBON

Grégory MAUBON is Chief Data Officer and digital coordinator at HCS Pharma, a biotech startup focused in high content screening and complex diseases. He manages IT missions and leads digital usages linked to company needs. He is also a Augmented Reality Evangelist (presenter and lecturer) since 2008, where he created www.augmented-reality.fr and founded in 2010 RA'pro (the augmented reality promotion association). He helped many companies (in several domains) to define precisely their augmented reality needs and supported them in the implementation.

2 Comments

Last day in Cosm’ing 2016 | HCS-pharma · July 1, 2016 at 9:04 am

[…] to go and discuss with Julian BURSZTYKA, our COO. He presents our work in HCS Pharma by showing a poster on genotoxicity assay, developped in collaboration with Toxicology in vitro team of Galderma R&D and he will give a […]

Cosm’ing 2016, a great meeting for us ! | HCS-pharma · July 13, 2016 at 9:00 am

[…] to the 7th Cosm’ing event, on cosmetic ingredients & biotechnology. He presented a poster on the assessment of genotoxic properties through gammaH2AX and comet assays, by High Content Screening, from a collaborative work done with Galderma. The scientific committee […]

Leave a Reply